lunes, 28 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 17, 2025

Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica

View original at finance.yahoo.com
Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica AstuteAnalytica India Pvt…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SHL Medical has set a goal to produce 1.5 billion devices annually by 2025

    80% confidence

  • The global drug delivery devices market size was valued at US$212.6 billion in 2025 and is projected to reach US$450.7 billion by 2035, growing at a CAGR of 7.8% during the forecast period 2026-2035

    80% confidence

  • The drug delivery devices market is entering a super-cycle fueled by an unprecedented convergence of chronic disease prevalence and biologic demand

    80% confidence

  • Eli Lilly's total manufacturing pledge reached over US$50 billion between 2020 and early 2025

    80% confidence

  • Such spending signals a permanent shift from outsourcing toward internalizing critical device production

    80% confidence

  • The market is surging due to the rising prevalence of chronic diseases and a massive shift toward home-based self-administration

    80% confidence

  • The drug delivery devices market has become the central pillar of pharmaceutical value creation

    80% confidence

  • Investment magnitude in the drug delivery devices market has reached historic levels as companies race to secure capacity

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · novel drug approvals61 approvals
U.S. Food and Drug Administration · first in class approvals24 approvals
U.S. Food and Drug Administration · breakthrough therapy approvals18 approvals
U.S. Food and Drug Administration · biosimilar approvals18 approvals
U.S. Food and Drug Administration · rare disease approvals26 approvals
U.S. Food and Drug Administration · priority review approvals28 approvals
U.S. Food and Drug Administration · fast track approvals22 approvals
U.S. Food and Drug Administration · first cycle approvals37 approvals
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,306 documentos fuente archivados
Consulta estos datos → isubstrate.com
Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica — Source | Via News | es.VIA.NEWS